Mont-Saint-Guibert, Belgium – August 8, 2025, 10:10pm CET / 4:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough ...
The U.S. Food and Drug Administration has approved the first fully implantable neurostimulator as a treatment for obstructive sleep apnea, according to a news release by Minneapolis-based Inspire ...
Everyday Health on MSN
Obstructive sleep apnea (OSA) and your health: Why OSA is a diabetes and heart health risk
In addition to affecting your sleep, obstructive sleep apnea (OSA) poses risks to your heart, metabolic health, and brain function if untreated.
Nyxoah NYXH recently received FDA approval for its Genio system, an innovative therapy for moderate to severe Obstructive Sleep Apnea (OSA). Featuring a leadless, battery-free design powered by an ...
AIOMEGA® announced the first prescribed clinical use of AIO BREATHE® mandibular repositioning device, FDA-cleared for ...
MELBOURNE, Australia and NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, announces ...
Everyday Health on MSN
CPAP vs. medication: Which obstructive sleep apnea (OSA) treatment is more effective?
Compare the efficacy, benefits, and drawbacks of CPAP therapy and tirzepatide (Zepbound), two of the best treatments for sleep apnea.
The MarketWatch News Department was not involved in the creation of this content. ATLANTA, Dec. 17, 2025 /PRNewswire/ -- Huxley Medical, Inc. today announced the U.S. Food and Drug Administration (FDA ...
CHICAGO -- An investigational proximal hypoglossal nerve stimulation device helped control obstructive sleep apnea (OSA), the OSPREY randomized trial showed. The Apnea-Hypopnea Index (AHI) response ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results